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Conclusion: Limited very low quality evidence is available to support the potential benefit of levonorgestrel
intrauterine devices for the prevention of pelvic inflammatory disease. Research results are conflicting and
there is a small amount of very low quality evidence to support this theory. Based on the current research
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Abstract   
 
Background:  Pelvic inflammatory disease is a community-acquired infection accounting for 
approximately 1.2 million hospital visits and $1.88 billion in cost annually in the United States. Few 
interventions are available for the prevention of pelvic inflammatory disease. Intrauterine devices are 
a well established method of contraception, in addition, levonorgestrel-releasing intrauterine devices 
may provide a protective advantage against pelvic inflammatory disease. This review aims to evaluate 
the available evidence to determine if levonorgestrel intrauterine devices, in addition to contraception, 
provide a protective benefit against pelvic inflammatory disease when compared to other intrauterine 
devices. 
Method:  An extensive literature search was performed using the databases MEDLINE , Web of 
Science, and CINAHL. Duplicate results and non-English articles were excluded. Articles meeting 
inclusion criteria were analyzed using the GRADE system. 
Results:  The literature search identified three articles that met inclusion criteria. All studies were 
randomized comparison trials involving a levonorgestrel intrauterine device compared to one or more 
forms of copper intrauterine device. Studies showed conflicting evidence supporting the benefit of 
levonorgestrel intrauterine devices for the prevention of pelvic inflammatory disease. All studies were 
of very low quality. 
Conclusion: Limited very low quality evidence is available to support the potential benefit of 
levonorgestrel intrauterine devices for the prevention of pelvic inflammatory disease. Research results 
are conflicting and there is a small amount of very low quality evidence to support this theory. Based 
on the current research levonorgestrel intrauterine devices for the prevention of pelvic inflammatory 
disease are not recommended. Further well designed prognostic studies are needed to determine the 
protective potential of levonorgestrel intrauterine devices. 
Keywords:  intrauterine device, levonorgestrel, intrauterine device copper, pelvic inflammatory 
disease 
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Levonorgestrel-Releasing Intrauterine Device for the Prevention of Pelvic 
Inflammatory Disease: A Systematic Review 
BACKGROUND 
Pelvic inflammatory disease (PID) is a community-acquired infection of female 
reproductive organs caused by a sexually transmitted disease, most commonly Neisseria 
gonorrhoeae and Chlamydia trachomatis. It may involve the uterus, fallopian tubes, ovaries, 
or all of these structures. PID is the most common gynecological condition seen in 
emergency departments in the United States and accounts for approximately 1.2 million 
hospital visits per year.1 In addition, an estimated annual cost of $1.88 billion is attributed to 
PID and its sequelae.2 Women who are celibate are not at risk for developing PID and 
women in long-term monogamous relationships are at very low risk.3 Women at greatest risk 
for developing PID are those between the ages of 15 to 25, women with multiple sexual 
partners, those with a male partner with a sexually transmitted infection, and those with a 
prior history of PID.3-6 Even with prompt diagnosis and treatment of PID long-term 
complications often occur. Sequelae of PID include recurrent episodes of PID, infertility, 
chronic pelvic pain, ectopic pregnancy, and possibly an association with increased risk of 
ovarian cancer.7 Long-term effects of PID are thought to be due to the scarring and adhesions 
that develop as a result of  tissue damage caused by infection and the natural healing process. 
These processes take place even in women with mild infections and resolution of symptoms.8  
Few interventions are available for the prevention of PID. Condoms are the most effective 
intervention for protecting against PID and may reduce gonococcal and chlamydial infections 
by as much as 50 percent.9 However, condom use must be correct and consistent to be 
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effective in the prevention of PID. Progestin-based contraceptives may decrease the risk of 
PID. Progestin-based contraceptives increase the viscosity of cervical mucus creating a 
barrier to sperm ascension into the uterus.10 The same mechanism may also create a barrier 
for ascending infection.8  
Intrauterine devices (IUDs) are one of the oldest methods of contraception, dating 
back to the early 1900s.11 They are a very safe and reliable method of contraception and their 
efficacy has been compared to that of female sterilization.12,13 In America there seems to be a 
persistent preconceived notion among medical providers and the general public, that IUDs 
cause an increased risk of PID.14 This could be due to a model of IUD available in the United 
States in the 1970s called the Dalkon Shield. This device was later shown to cause an 
increased risk of PID because the multifilament tail strings of the device were porous and 
allowed bacteria to ascend easily into the uterus, causing infection. The Dalkon Shield was 
removed from the market in 1974,14 and since that time, studies have shown that the risk of 
PID in patients with IUDs is similar to the risk of PID in the general population, with only a 
slight increase in risk for the first 20 days after insertion.15 In 2007 the American College of 
Obstetrics and Gynecology (ACOG) released a Committee Opinion stating that IUDs were 
an acceptable method of contraception for adolescent and nulliparous women and considered 
first-line therapy as a contraceptive method in these groups.16 Not only does ACOG state that 
IUDs are acceptable for use in teens and efficacious in preventing contraception, but 
levonorgestrel-releasing IUDs may actually protect women against PID.16 In addition to 
ACOG, UpToDate and several other articles also make reference to the idea that LNG IUDs 
may have a protective effect against PID.13, 17-19 
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In the United States there are currently two IUDs available on the market. The first is 
the Paragard IUD, which consists of a copper wire wound around a T-shaped polyethylene 
frame. Paragard was approved by the FDA in 1984 and has an effective treatment life of 10 
years.20 The second is the Mirena IUD, which contains the synthetic hormone levonorgestrel. 
Mirena, also a T-shaped polyethylene device, contains a hormone reservoir around the 
vertical stem. The device releases 20 mcg of levonorgestrel daily and has a treatment life of 5 
years.21 Levonorgestrel achieves its contraceptive effect by acting directly on the endometrial 
layer causing atrophy and thinning and by increasing the viscosity of cervical mucus in much 
the same way as progestin-based contraceptives do.21, 22 
The prevention of PID is of critical importance to those at risk for developing PID 
and to those responsible for covering the substantial annual cost of the disease. If 
levonorgestrel IUDs are shown to reduce the risk of PID in comparison to other IUDs then 
they may become an important first-line therapy in the prevention of PID. This review aims 
to determine if the current evidence supports the potential benefit of levonorgestrel-releasing 
IUDs in decreasing a woman’s risk of developing PID. 
METHODS 
Search Design 
An exhaustive literature search was conducted using the databases MEDLINE (Ovid), 
Web of Science, and CINAHL (EBSCOhost). Search terms included intrauterine device, 
levonorgestrel, and intrauterine device copper. Duplicate results were removed and 
remaining results were screened. In addition to the database search, references of all included 
studies as well as reputable medical resources were reviewed for additional articles. Medical 
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resources included UpToDate and Medscape. The abstracts of the articles were analyzed to 
identify randomized control trials comparing levonorgestrel-releasing and copper-releasing 
intrauterine devices. 
Inclusion Criteria 
Articles were required to be English language, randomized comparison trials, studies 
including a direct comparison of levonorgestrel and copper-releasing IUDs, and include 
pelvic inflammatory disease as an outcome.  
Quality Assessment 
The studies were evaluated for quality and validity of findings using the GRADE 
system.23 The GRADE system analyzes studies based on methodology, consistency of 
results, directness of evidence, and risk of publication bias. The quality of each study was 
categorized as high, moderate, low, or very low.  
RESULTS 
A total of 331 articles results were found in the search, and thirty-three potential 
articles were identified after duplicates and irrelevant articles were removed. Of these, three 
studies met the inclusion criteria. All studies were randomized comparison trials. Two of the 
studies were open studies in which no blinding occurred.12,24 The third study employed only 
blinding of the study subjects, not the study researchers.25 All studies compared a 
levonorgestrel-releasing IUD to one or more forms of copper-releasing IUD. All studies 
followed patients for a minimum of three years and had low lost to follow up numbers. 12, 21-22  
(See Table I: Characteristics of Reviewed Studies.) The studies by Sivin et al25 and 
Andersson et al12 published articles throughout the course of the research reviewing and 
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analyzing data as it became available. For the purpose of this review the most recent articles 
which compile the entirety of that data for each study was used.12, 25 
Baveja et al (1989) 
The Indian Council of Medical Research conducted a study at fifteen Human 
Reproductive Research Centres throughout India beginning in August 1983. The purpose of 
the study was to compare the newer levonorgestrel IUDs, and the Copper T 380Ag and 
Copper T 220C IUDs to the Copper T 200B IUD which was in use in India at the time. The 
daily dose of levonorgestrel released from the IUD in the study is not described.24  
The study design called for 2400 patients, 600 patients per device. Researchers enrolled 1905 
healthy female patients age 18 to 40 with proven fertility in the study. Patients were 
randomized to one of four study groups. The randomization process was concealed using a 
computer program. Study centres were provided with sealed numbered envelopes containing 
the devices. Envelopes contained information identifying the device. At the time of device 
placement patient and researchers became aware of which type of device was received. There 
were 475 patients randomized to the LNG IUD group, 434 to the Copper T 380Ag IUD, 496 
to the Copper T 220C IUD, and 500 to the Copper T 200B IUD. The optimum number of 
patients outlined in the study design was not achieved due to two factors, one of the centres 
dropped out of the study and study participant information could not be obtained, and 
researchers had an inadequate supply of LNG IUDs. Study groups were similar in prognostic 
factors. Analysis of study group characteristics yielded no statistical difference in 
characteristics among groups. Loss to follow up was low, ranging from 7.2 to 10.3 percent, 
with no statistically significant difference between groups.24  
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The researchers in this study were most concerned with the continuation rate of the 
various devices and analyzed the reason the devices were discontinued to document the 
variation. Discontinuation rates between copper devices were similar with 50.4% of the 
Copper T 380Ag users, 45.4% of the Copper T 220C users, and 45, 4% of the Copper T 
200B users continuing use at three years. However, discontinuation of the LNG device was 
higher compared to the other devices and this difference was statistically significant with a P-
value <0.01. Only 38.8% of LNG users continued use at three years. The most significant 
reason for discontinuation of the LNG device was menstrual abnormalities. Unintended 
pregnancy occurred at different rates between devices. Pregnancy rates per 100 women were 
1.0 in the Copper T 380Ag group, 0.3 in the Copper T 220C group, and 1.6 in the Copper T 
200B group, with no pregnancies occurring in the LNG group. The difference was not 
statistically significant according to the study.24 
Other reasons for discontinuation of use, in addition to unintended pregnancy and 
menstrual abnormalities, were expulsion of device, perforation, and pelvic and vaginal 
infection. Sixteen cases of pelvic infection occurred during the course of the study. There is 
no significant difference in the rates of PID between devices and confidence intervals are 
narrow. Over the course of the three year trial PID occurred at a rate of 1.8 (95% CI, 0.4-3.2) 
per 100 women in the LNG IUD group, 1.2 (95% CI, 0.0-2.4) in the Copper T 380Ag group, 
1.7(95% CI, 0.3-3.1) in the Copper T 220C group, and 1.2 (95% CI, 0.2-2.2) in the Copper T 
200B group.24 
Sivin et al (1994) 
The Population Council’s International Committee for Contraception Research 
sponsored a multicenter international study to measure and compare the effectiveness as well 
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as advantages and disadvantages of two types of 20 mcg/day levonorgestrel IUD compared 
to a copper-releasing IUD. The study took place over the course of seven years. Originally 
the study was designed to be a five years trial but during the course of the study the 60mg 
LNG IUD was found to have an effective treatment life of up to seven years and the study 
was extended.25 
Patient enrollment into the study began in September 1981. Researchers enrolled 
2246 healthy female patients age 18-38 desiring contraception into the study. A total of 1125 
women were randomized to the LNG IUD group and 1121 to the copper IUD group. IUDs 
were individually packaged in opaque envelopes and numbered. Patients agreed to both 
randomization and blinding and were randomly assigned a number corresponding to an 
envelope. Researchers were not blinded in the study. Patients were similar in prognostic 
factors. Loss to follow up was low, 11.5 percent in the LNG group and 16.2 percent in the 
copper IUD group.22  
Several outcomes related to device discontinuation were evaluated in the study. 
Reasons for discontinuation of the IUD included pregnancy, expulsion of device, 
amenorrhea, menstrual concerns/pain, PID, endometritis, planning pregnancy, other personal 
reasons, and a variety of other medical concerns. Examples of other medical concerns 
include skin/hair conditions, headache, depression, gastrointestinal tract concerns, and 
vaginitis. Discontinuation due to pregnancy occurred at a rate of 1.1 (95% CI, 0.1-2.1) per 
100 women in the LNG IUD group and a rate of 1.4 (5% CI0.6-2.2) per 100 women in the 
copper IUD group with no statistically significant difference in rate. Rates of amenorrhea per 
100 women occurred at 4.4 in the LNG group and 0.1 in the copper group, which was 
significant with a P-value <0.001.25 
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There were a total of 48 cases of PID throughout the study, 24 in each group. Over 
the course of the study PID occurred at a rate of 0.7 per 100 years in the LNG group and 0.7 
per 100 years in the Cu IUD group. There was no statistically significant difference in rates 
of PID between groups.25-26 
 
Andersson et al (1994) 
The study was carried out in a total of twelve clinics located in Finland, Sweden, 
Denmark, Hungary, and Norway. The purpose of the European based study was to compare 
the contraceptive efficacy and clinical performance of a 20 mcg/day levonorgestrel IUD to 
the Nova T, a type of copper IUD. Study enrollment began in November 1982 and concluded 
in December 1984 and patients were followed for 5 years.12 
The study design called for a minimum of 1000 patients per group to be able to detect 
significant differences in contraceptive efficacy between devices. Researchers also decided to 
allocate the LNG and copper devices in a 2:1 fashion in order to detect more reliably rare 
side effects that may be associated with the LNG IUD. In the study protocol the diagnosis of 
PID included salpingo-oophoritis, tubo-ovarian abscess, and pelvic peritonisit. The diagnosis 
of PID required at least two of the following signs and symptoms; history of lower 
abdominal pain and temperature greater than 38 Celsius, sedimentation rate above 30 
mm/hour, tenderness on pelvic exam, mass on pelvic exam, or evidence on ultrasound or 
laparoscopy if clinical evidence was controversial. A total of 2758 healthy women ages 18-
38 desiring contraception were enrolled in the study. Within the study group 1821 were 
randomized to the LNG IUD group and 937 to the Nova T group. IUDs were randomized and 
placed in sealed numbered envelopes at a central location then supplied to the study sites. No 
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blinding occurred in the study because researchers felt providers would better be able to 
counsel patients on expected side effects if the device type was known. Patient groups were 
similar and there was no statistically significant difference in study groups. Loss to follow up 
was low at 14% in the LNG IUD group and 6.3% in the Nova T group.12 
Continuation rates at the end of the five-year study were 44.5 % in the LNG IUD 
group and 46.9% in the Nova T group. Reasons for device discontinuation include 
pregnancy, expulsion of device, bleeding problems, amenorrhea, pain, PID, hormonal side 
effects such as depression and acne, personal reasons, and other medical reasons including 
enlarged follicles and hypertension. Pregnancy occurred at a rate of 0.5 in the LNG group 
and 5.9 in the Nova T group. The difference in rates demonstrated a statistically significant 
difference with a P-value <0.001. Discontinuation due to amenorrhea occurred at a rate of 6.0 
in the LNG group and there were no patients in the Nova T group who discontinued the IUD 
for this reason. The difference in rates of amenorrhea was also statistically significant with a 
P-value <0.001.12 
Pelvic infection occurred at an overall rate of 0.8 in the LNG IUD group and 2.2 in 
the Nova T group. The difference in rates is statistically significant, however, the P-value in 
relation to this data is denoted differently in two separate places. Within the body of the text 
the P-value is denoted as <0.05, in Table 3 it is listed at ≤0.01. In addition, the difference in 
rates of PID in the 25 and under age group was even more substantial with a P-value ≤0.01. 
In this group PID occurred at a rate of 0.3 in the LNG group and 5.6 in the Nova T group 
over the course of the study. The rates of occurrence outlined are a measure of cumulative 
gross rates over the course of the seven-year study.12 
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DISCUSSION 
The studies reviewed demonstrate conflicting evidence to support the theory that 
LNG IUDs protect against PID. All studies reviewed contain their own flaws in methodology 
and allow for potential bias to be introduced. PID is a secondary outcome in all three studies 
making the results in regard to this outcome inherently weak. In addition, none of the studies 
include women under the age of 18 which excludes a large portion of the group most at risk 
for developing PID (See Table I).12, 24-25 Also, only one of the studies clearly outlines their 
diagnostic criteria for PID which allows their diagnosis of PID to be consistent between 
providers.12 The other two studies provide no criteria for the diagnosis of PID allowing for 
potential variability between providers.21,22 There is little variability between studies in 
regards to patient age range or the types of intervention being studied, however, patient 
populations are very different in regard to location. It is possible that because patient 
populations are from a variety of global locations, local cultural practices and beliefs could 
influence female’s sexual practices in these areas leading to variation in their risk of PID. 
Overall, these studies are insufficient to prove or disprove the potential protective effect of 
LNG IUDs. The current available data does not have the power to change the current practice 
for IUD use. Further well designed and well conducted studies would be needed to determine 
the actual effect of LNG IUDs on development of PID. 
In the article by Baveja et al24 although the study was a randomized comparative trial 
there is a lack of blinding of both patients and researchers limiting the effectiveness of their 
methodology. There are no apparent inconstancies in their results, however, the outcome of 
PID is a secondary outcome in this study leading to some indirectness of evidence in regards 
to the question at hand. There is also a lack of precision evident in this study due to the fact 
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that the calculated optimum number of patients was not enrolled as mentioned earlier. The 
research organization was examining the possible use of the LNG IUD in India and 
concluded at the end of the study that they would not change the national use of the copper 
IUD even though LNG IUD had a higher efficacy at preventing pregnancy. This suggests 
there is a potential for publication bias because the Indian Council of Medical Research was 
possibly under pressure to make cost effective decisions for the country. Therefore, the 
overall GRADE for the quality of this study is very low. 
Sivin et al25 attempted only single blinding in their randomized control trial, limiting 
the effect of their methodology. There is no evidence of inconsistencies in their results. There 
is a degree of indirectness of evidence because PID in this study is also a secondary outcome. 
In addition, it is unclear if there is a lack of precision in the findings because confidence 
intervals and standard deviations are not outlined for all outcomes in the study. There appears 
to be a low likelihood of publication bias,25 however, due to the characteristics of the study 
the overall GRADE assessment is very low. 
The randomized control trial published by Andersson et al12 makes no attempt at 
blinding study participants or researchers leading to limitations in their methodology. In 
addition it is unclear from the study how the researchers obtained the numbers they use for 
their statistical analysis. For example, it is unclear how they extrapolate the gross rate that is 
outlined in Table 3 based on number of patients who became pregnant during the course of 
the study, thus leading to concerns about inconsistency in their results. The numbers that are 
noted for net cumulative rates per 100 per year in Table 2 of the study do not correlate with 
the cumulative gross rates in Table 3. There is also concern for indirectness of evidence 
because PID in this study, like the others, is a secondary outcome. Since confidence intervals 
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and standard deviations are not given there is concern for lack of precision of results.12 
Finally, there is some controversy alluding to potential researcher bias that is indicated in 
statements made by other research teams.27 Regardless of the potential for publication bias, 
the overall GRADE for the quality of evidence outlined in this study is very low as well. 
Due to the very low quality of evidence regarding LNG IUDs and their potential 
protective effect against PID it seems that additional research could have a considerable 
impact on future practice. Additional studies are certainly needed to determine the actual 
effect of LNG IUDs on decreasing rates of PID. A randomized comparative trial is not the 
best study design for a question of this nature. A prognostic study involving women at 
highest risk for developing PID, those ages 15 to 25, would be ideal. By performing a 
prognostic study researchers would be able to take a group of women at risk of the target 
event, in this case PID, who are using either a LNG or copper IUD and follow them over a 
period of time to determine at what rates each group experiences the target outcome. A 
prognostic study would more clearly demonstrate the actual effect of LNG on the rates of 
PID and better guide medical practice in the future.  
CONCLUSION 
There is minimal low quality evidence available to support the statement that LNG 
IUDs are protective against PID. Yet, several articles make reference to this theory and in 
some cases almost as if it is fact. There is a degree of controversy surrounding this idea and 
we lack the supporting evidence to bring this theory forward into practice. Further 
investigation of the potential protective effect is needed and could greatly impact the use of 
the levonorgestrel IUDs in modern medical practice. 
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Table I. Characteristics of Reviewed Studies 
 
Study Design Age Range 
Number of 
Study 
Participants 
Randomization Blinding 
Prognostic 
Factors Similar 
Among Groups 
Follow-up 
Complete 
Loss to 
Follow-up  
Length of 
Follow-up 
Period 
Baveja et al21 Randomized 
Comparison 
Trial 
18 to 40 1905 (475 
LNG, 1430 
Cu) 
Adequate None Yes Yes 7.2 to 10.3% 
per group 
 3 years 
Sivin et al22 Randomized 
Comparison 
Trial 
18 to 38 2246 (1125 
LNG, 1121 
Cu) 
Adequate Single 
(patient 
only) 
Yes Yes 11.5% in 
LNG group, 
16.2% in Cu 
 
5-7 years  
Andersson et al12 Randomized 
Comparison 
Trial 
18 to 38 2758 (1821 
LNG, 937 Cu) 
Adequate None Yes Yes 14% in LNG 
group, 6.3% 
in Cu group 
5 years 
 
Table I continued 
Study 
Precision 
(CI, p-values, 
SD) 
PID Primary 
outcome Y/N? Other Considerations GRADE 
Baveja et al21 SD, some p-values 
<0.001, <0.01, and 
<0.05 
No  # of study patients lower 
 than optimal # 
very low 
Sivin et al22 p-values <0.001, 
<0.01, and <0.05, 
no CI or SD 
No  none very low 
Andersson et al12 p-values <0.001, 
<0.01, and <0.05, 
no CI or SD 
No  method of statistical 
analysis unclear 
very low 
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Table II. Summary of Findings 
 
 
Study 
 
Rates of PID  
 
P-value 
 
Confidence 
intervals 
 
GRADE 
Baveja et al21 LNG- 1.8 
Cu380Ag- 1.2 
CuT220C- 1.7 
Cu200B- 1.2 
Not 
significant, 
P >0.001 
LNG: 0.4-3.2 
CuT380Ag: 0.0-2.4 
CuT220C: 0.3-3.1 
Cu200B: 0.2-2.2 
very low 
Sivin et al22 LNG- 0.7 
TCu380Ag- 0.7 
Not 
significant 
None given very low 
Andersson et al12 LNG- 0.8 
Nova T- 2.2 
Significant, 
P<0.01 
None given very low 
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